Abstract
Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths anticipated in 2012.1 While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 y.1,2 Host anti-tumor immune responses are associated with a significant improvement in overall survival for women with ovarian cancer.3,4 By bolstering these responses, it may therefore be possible to significantly influence the prognosis of women with this lethal disease. In this review, we will focus on innovative immune-based strategies which are currently being investigated in the treatment of ovarian cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1179-1191 |
| Number of pages | 13 |
| Journal | Human Vaccines and Immunotherapeutics |
| Volume | 8 |
| Issue number | 9 |
| DOIs | |
| State | Published - Aug 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antibodies, Monoclonal/therapeutic use
- Female
- Humans
- Immunotherapy, Adoptive
- Immunotherapy/methods
- Ovarian Neoplasms/drug therapy
Fingerprint
Dive into the research topics of 'Immunotherapy in ovarian cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver